Advanced Glaucoma Clinical Trial
Official title:
Effect of OXSIGHT Smart Glasses on Patients With Advanced Glaucoma
Glaucoma is the leading cause of irreversible blindness worldwide. The visual function of patients with advanced glaucoma is severely impaired, and the vision-related activities (e.g. movement, reading) are obviously restricted, which may have a negative impact on the patients' quality of life (QOL) and increase the burden on individuals and families. Low vision aids (LVAs) and other devices for vision rehabilitation (VR) are useful for patients with advanced glaucoma to maximize the function of residual vision and improve the QOL. OXSIGHT smart glasses are the latest LVAs eyeglasses that are expected to improve the QOL for patients with low vision (LV), such as those with glaucoma. Clinical data were collected to evaluate the efficacy and its influencing factors of OXSIGHT smart glasses in patients with advanced glaucoma, in providing theoretical basis for subsequent clinical studies.
1. Glaucomatous low vision. Glaucoma is a chronic eye disease that causes irreversible
damage to the optic nerve and can lead to severe vision loss and blindness. Low vision
(LV) is a decrease in vision that cannot be corrected with standard glasses, contact
lenses, medication or surgery, impairing a person's ability to perform age-appropriate
vision-dependent tasks.
2. Low vision rehabilitation. Low Vision Rehabilitation (LVR) is part of the continuum of
eye care that extends from diagnosis to treatment and rehabilitation, designed to help
visually impaired patients retain vision to the maximum, make activities easier to
perform, regain independence, and improve their QOL. LVR services include comprehensive
assessment of visual function, prescription of LVAs, rehabilitation training and
referrals to a range of community services and psychosocial support.
3. Research status of intelligent head-mounted devices. In recent years, video head-mounted
devices have been gradually applied in the field of VR, with the advantages of high
definition, diverse processing modes, adjustable magnification, contrast and brightness,
which overcome the limitations of traditional devices, like eSight 3, NuEyes, and
IrisVision. However, studies on the effectiveness of head-mounted electronic LVAs are
quite limited.
4. OXSIGHT smart glasses. OXSIGHT smart glasses, the latest generation of head-mounted
electronic LVAs, developed by the team of Oxford University in the UK, are designed for
LV patients with visual field defects. Based on the previous generation, OXSIGHT has the
advantages of lighter weight, comfortable wearing, better imaging quality, multi-mode
assisted visual recognition and so on. However, the efficacy and influencing factors of
OXSIGHT smart glasses on advanced glaucoma patients remain unclear, and further studies
are needed.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02173223 -
A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt
|
Phase 2 | |
| Recruiting |
NCT00349414 -
Safety Study of Conventional Versus Micropulse Transscleral Cyclophotocoagulation in Treating End-Stage Glaucoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00453024 -
Imaging Ahmed Glaucoma Tubes With a Pericardial Graft and Tissue Glue or Partial-Thickness Scleral Flap and Sutures
|
Phase 2 |